Pharyngeal spreading of peri-implant infections under antiresorptive/antiangiogenic therapy
Tóm tắt
To assess the influence of antiresorptive/antiangiogenic therapy on the spreading of peri-implant infections in the pharyngeal region. This analysis was based on tissue biopsies obtained from a total of twenty-five albino rats having either received (1) amino-bisphosphonate (Zoledronate) (Zo) (n=4), (2) RANKL inhibitor (Denosumab) (De) (n=4), (3) antiangiogenic medication (Bevacizumab) (Be) (n=4), (4) Zo+Be (n=3), (5) De+Be (n=5), or (6) no medication (Co) (n=5). Drug administration was repeated at 12 weeks. Chronic-type peri-implant infections were induced at titanium implants located in the upper jaws. The surface area (%) of infiltrated connective tissue (ICT) and CD68-positive cells was assessed within the lateral pharyngeal/retropharyngeal connective tissue zone. Mean (±SD) and median ICT% values and CD68 counts were markedly highest in the De+Be (11.10±6.04; 11.81; 95% CI − 3.89; 26.11) and De (5.70±5.06; 6.19; 95% CI − 2.34; 13.75) groups, reaching statistical significance for De CD68 counts over the Co (0.18±0.25; 0.18; 95% CI −2.14; 2.51) group. In both De+Be and De groups, the ICTs were occasionally associated with an ulceration of the epithelial compartment. Induced peri-implant infections were not associated with any inflammatory lesions in pharyngeal tissues. While these findings were similar under Zo and Be medication, De and De+Be had a marked effect on ICT and CD68 values. The clinical relevance of these adverse findings needs further investigation.
Tài liệu tham khảo
Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. J Clin Periodontol. 2018;45(Suppl 20):246–66.
Carcuac O, Berglundh T. Composition of human peri-implantitis and periodontitis lesions. J Dent Res. 2014;93(11):1083–8. https://doi.org/10.1177/0022034514551754.
Berglundh T, Gislason O, Lekholm U, Sennerby L, Lindhe J. Histopathological observations of human periimplantitis lesions. J Clin Periodontol. 2004;31(5):341–7. https://doi.org/10.1111/j.1600-051X.2004.00486.x.
Carcuac O, Abrahamsson I, Derks J, Petzold M, Berglundh T. Spontaneous progression of experimental peri-implantitis in augmented and pristine bone: a pre-clinical in vivo study. Clin Oral Implants Res. 2020;31(2):192–200. https://doi.org/10.1111/clr.13564.
Watts NB. Bisphosphonate treatment of osteoporosis. Clin Geriatr Med. 2003;19(2):395–414. https://doi.org/10.1016/S0749-0690(02)00069-1.
Sharma NS, Ooi JL, Masselos K, Hooper MJ, Francis IC. Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med. 2008;359(13):1410–1. https://doi.org/10.1056/NEJMc0803366.
Kaneko J, Okinaga T, Hikiji H, Ariyoshi W, Yoshiga D, Habu M, et al. Zoledronic acid exacerbates inflammation through M1 macrophage polarization. Inflamm Regen. 2018;38(1):16. https://doi.org/10.1186/s41232-018-0074-9.
Kennel KA, Drake MT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc. 2009;84(7):632–7; quiz 638. https://doi.org/10.1016/S0025-6196(11)60752-0.
Wynn RL. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw. Gen Dent. 2011;59(6):410–3.
Fusco V, Porta C, Saia G, Paglino C, Bettini G, Scoletta M, et al. Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer. 2015;13(4):287–94. https://doi.org/10.1016/j.clgc.2014.12.002.
Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev. 2015;41(5):455–64. https://doi.org/10.1016/j.ctrv.2015.04.007.
Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181–8. https://doi.org/10.1007/s10549-010-0866-3.
Francisconi CF, Vieira AE, Azevedo MCS, Tabanez AP, Fonseca AC, Trombone APF, et al. RANKL triggers Treg-mediated immunoregulation in inflammatory osteolysis. J Dent Res. 2018;97(8):917–27. https://doi.org/10.1177/0022034518759302.
Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int. 2011;22(2):435–46. https://doi.org/10.1007/s00198-010-1326-y.
Moghimi M, Baart JA, Karagozoglu KH, Forouzanfar T. Spread of odontogenic infections: a retrospective analysis and review of the literature. Quintessence Int. 2013;44(4):351–61. https://doi.org/10.3290/j.qi.a29150.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG. and N.C.R.R.G.W. Group, Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol. 2010;160(7):1577–9. https://doi.org/10.1111/j.1476-5381.2010.00872.x.
Takamori Y, Atsuta I, Nakamura H, Sawase T, Koyano K, Hara Y. Histopathological comparison of the onset of peri-implantitis and periodontitis in rats. Clin Oral Implants Res. 2017;28(2):163–70. https://doi.org/10.1111/clr.12777.
Yu X, Hu Y, Freire M, Yu P, Kawai T, Han X. Role of toll-like receptor 2 in inflammation and alveolar bone loss in experimental peri-implantitis versus periodontitis. J Periodontal Res. 2018;53(1):98–106. https://doi.org/10.1111/jre.12492.
Al-Maawi S, Vorakulpipat C, Orlowska A, Zrnc TA, Sader RA, Kirkpatrick CJ, et al. In vivo implantation of a bovine-derived collagen membrane leads to changes in the physiological cellular pattern of wound healing by the induction of multinucleated giant cells: an adverse reaction? Front Bioeng Biotechnol. 2018;6:104. https://doi.org/10.3389/fbioe.2018.00104.
Galarraga-Vinueza ME, Obreja K, Ramanauskaite A, Magini R, Begic A, Sader R, et al. Macrophage polarization in peri-implantitis lesions. Clin Oral Investig. 2020;25(4):2335–44. https://doi.org/10.1007/s00784-020-03556-2.
Sanz M, Alandez J, Lazaro P, Calvo JL, Quirynen M, van Steenberghe D. Histo-pathologic characteristics of peri-implant soft tissues in Branemark implants with 2 distinct clinical and radiological patterns. Clin Oral Implants Res. 1991;2(3):128–34. https://doi.org/10.1034/j.1600-0501.1991.020305.x.
Gualini F, Berglundh T. Immunohistochemical characteristics of inflammatory lesions at implants. J Clin Periodontol. 2003;30(1):14–8. https://doi.org/10.1034/j.1600-051X.2003.300103.x.
Bullon P, Fioroni M, Goteri G, Rubini C, Battino M. Immunohistochemical analysis of soft tissues in implants with healthy and peri-implantitis condition, and aggressive periodontitis. Clin Oral Implants Res. 2004;15(5):553–9. https://doi.org/10.1111/j.1600-0501.2004.01072.x.
Fretwurst T, Garaicoa-Pazmino C, Nelson K, Giannobile WV, Squarize CH, Larsson L, et al. Characterization of macrophages infiltrating peri-implantitis lesions. Clin Oral Implants Res. 2020;31(3):274–81.
Van Dyke TE, van Winkelhoff AJ. Infection and inflammatory mechanisms. J Clin Periodontol. 2013;40(Suppl 14):1–7.
van Winkelhoff AJ, Slots J. Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in nonoral infections. Periodontology. 1999;20:122–35.
Thoden van Velzen, S.K., L. Abraham-Inpijn, and W.R. Moorer, Plaque and systemic disease: a reappraisal of the focal infection concept. J Clin Periodontol 1984; 11(4): 209-220, DOI: https://doi.org/10.1111/j.1600-051X.1984.tb02211.x.
Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev. 2000;13(4):547–58. https://doi.org/10.1128/CMR.13.4.547.
Diker-Cohen T, Rosenberg D, Avni T, Shepshelovich D, Tsvetov G, Gafter-Gvili A. Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(5):1641–58. https://doi.org/10.1210/clinem/dgz322.
Silva-Fernandez L, Rosario MP, Martinez-Lopez JA, Carmona L, Loza E. Denosumab for the treatment of osteoporosis: a systematic literature review. Reumatol Clin. 2013;9(1):42–52. https://doi.org/10.1016/j.reuma.2012.06.007.
Paschalidi P, Gkouveris I, Soundia A, Kalfarentzos E, Vardas E, Georgaki M, et al. The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw. Clin Oral Investig. 2020. https://doi.org/10.1007/s00784-020-03602-z.
Qi WX, Fu S, Zhang Q, Guo XM. Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials. Crit Rev Oncol Hematol. 2015;94(3):323–36. https://doi.org/10.1016/j.critrevonc.2015.02.007.